Bloomberg / Mumbai September 26, 2008, 0:14 IST

American relief programme suspends funding for three generic medicines.

AIDS drugs made by Ranbaxy Laboratories won't be purchased under an American programme to supply medicines to developing countries after the US cited the company for violations in two of its plants.

D G Shah
Secretary General IPA*

A sense of doom is not at all warranted

THE recent FDA action is a warning for several other companies that are already in the US market or intend to enter it in the near future. Just as they had learnt to emulate the success of the pioneering efforts of Ranbaxy, they will learn the hard lessons from the recent experience of Ranbaxy.

Nina Mehta MUMBAI

Daiichi Sankyo has said that there are procedural delays in completing the open offer for acquiring an additional 20% equity of Ranbaxy. The delay pertains to payments to shareholders who have subscribed to the Japanese company's open offer for acquiring an additional 20% equity of Ranbaxy.

THE U.S. BAN ON some medicines made by India's largest pharmaceutical company adds a black mark against India's booming drug and drug-testing industries, which already have been under pressure over the country's lax monitoring of drug safety.

Bs Reporter / New Delhi/tokyo September 18, 2008, 0:30 IST

Lapses on record-keeping Affects numerous, widely-used medications
Preventive action to protect quality of drugs

Joe C Mathew / New Delhi August 27, 2008, 0:39 IST

Firm reaches out-of-court agreement on 5 of 19 patent challenges in the US.

Ranbaxy Laboratories, India's largest pharmaceutical drug firm by sales, expects its recent patent litigation settlements to add significantly to its revenues as well as net profit. The numbers could run into billions of dollars, sources familiar with the company's strategy said.

The company, in the midst of being acquired for $4.6 billion by Daiichi Sankyo, had filed 19 patent challenges in the US, but has settled five of these in the last two years.

about a month after the Japanese drug company, Daiichi Sankyo, acquired majority shares in Ranbaxy, India

Joe C Mathew / New Delhi July 24, 2008, 0:03 IST

Two United States senators have asked the US Food and Drug Administration (USFDA) to provide details of market approvals given to all medicines sold by India's largest drug-maker Ranbaxy in that country.

The senators, John Dingell and Bart Stupak, also want the FDA inspectors who were in charge of drug approvals for Ranbaxy to appear before a House of Representatives committee by the end of August.